In Reply: Drs DePriest and Gonzalez and Dr Rady and colleagues raise important issues regarding dexmedetomidine and sepsis. Despite their suggestions, our primary population comprised intubated patients requiring sedation, and sepsis was a common associated diagnosis. The Investigational New Drug (IND) application for dexmedetomidine was approved by the FDA for this trial with doses from 0.2 to 1.4 μg/kg per hour (not greater than 1.4 μg/kg) for up to 30 days.
Riker RR, Shehabi Y, Rocha MG. Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU—Reply. JAMA. 2009;301(23):2439–2442. doi:10.1001/jama.2009.840
Customize your JAMA Network experience by selecting one or more topics from the list below.